Skip to content

To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi'

To Evaluate the Clinical Efficacy of Zhuanyao Decoction in the Treatment of Degenerative Lumbar Spinal Stenosis Based on the Theory of 'Yanghua Qi'

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046515
Enrollment
Unknown
Registered
2021-05-18
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lumbar spinal stenosis

Interventions

Sponsors

Wang Jing Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.It meets the diagnostic criteria of lumbar spinal stenosis in western medicine; 2.In line with the TCM syndrome differentiation standard of spleen-kidney qi deficiency, phlegm and blood stasis; 3.Aged 45 to 70 years; 4.VAS score was 3-7; 5.Lumbar MRI showed central canal stenosis caused by the thickening of facet joints and ligamentum flavum, without the stenosis of nerve root canal caused by disc herniation. 6.Voluntarily signed informed consent; 7.If the patient has received other methods of treatment, has passed more than 7 days of washout period. Only patients meet the above 7 criteria can be selected as eligible subjects for this clinical study.

Exclusion criteria

Exclusion criteria: 1.With lumbar intervertebral disc herniation, lumbar tuberculosis, spondylolisthesis, congenital lumbar stenosis or spinal stenosis caused by inflammation, tumor, trauma, surgery; 2.Patients with severe surgical indications (patients with lower limb paralysis and defecation dysfunction and bedridden); 3.Pregnant or within half a year to prepare for pregnancy, lactating women; 4.Patients with heart, brain, liver, kidney, hematopoietic system and other serious primary diseases; 5.People with allergies or known allergies to the drugs and their components used in this study; 6.Not suitable for the special population to participate in clinical research (blind, deaf, dumb, intellectual or mental disorders, etc.); 7.Patients enrolled in other clinical trials within 3 months. 8.Patients with contraindications to celecoxib capsule: contraindicated for coronary artery bypass bypass (CABG) surgery, active gastrointestinal ulcer/bleeding, severe heart failure, etc.. If any one of the above options is met, the case is excluded.

Design outcomes

Primary

MeasureTime frame
Intermittent claudication distance;Pain visual analogue scales score;Oswestry disability index;

Secondary

MeasureTime frame
Curative effect of lumbago disease;Lumbar motion;Traditional Chinese medicine syndrome integral;

Countries

China

Contacts

Public ContactGao Jinghua

Wang Jing Hospital, Chinese Academy of Traditional Chinese Medicine

gaojinghua64@sina.com+86 13552136871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026